ing type 2 diabetes (T2D) by 58% and 31% respectively, vs. controls. A model was developed to explore the longterm cost-effectiveness of DPP interventions in France, Germany, and UK. METHODS: A Markov model simulated 3 states: "IGT", "T2D", and "dead". Probabilities were derived from DPP and published mortality data. Life expectancy (LE) was calculated for each treatment arm. Country-specific direct costs were retrieved from published sources. Lifetime costs/patient (TC) were calculated. Incremental cost-effectiveness ratios were calculated (costs/life-year gained [C/LYG]). (TC and LE discounted 5% p.a.). Extensive sensitivity analysis was performed to identify parameters with important impacts on outcomes. RESULTS: Time to onset of diabetes was 8.27, 14.44, and 10.76 years for placebo, ILC, or metformin respectively. Delaying the onset of T2D with either ILC or MET improved discounted LE vs. placebo by 0.19 and 0.08 years respectively. ILC lead to TC increases vs. placebo of €2958, 1365, and 1707/patient for France, Germany and UK respectively; and for MET increases vs. placebo of €636, 374, and 316/patient for France, Germany and UK respectively. C/LYG were: France-ILC vs. placebo €15,568 and MET vs. placebo €7,950; Germany-ILC vs. placebo €7,184 and MET vs. placebo €4,675; and UK-ILC vs. placebo €8,984 and MET vs. placebo €3,950. Results were most sensitive to the probabilities of developing T2D, the relative risk of mortality for the state T2D compared to IGT, and the costs of implementing the DPP. CONCLUSIONS: ILC and MET delayed diabetes onset and lead to improvements in LE. Both ILC and MET were highly cost-effective in all 3 countries (i.e. C/LYG < €28,000).
1
CORE Center for Outcomes Research, Basel, Switzerland; 2 Ghent University, HEDM, Meise, Belgium; 3 HEDM, Meise, Belgium; 4 Sanofi-Synthelabo, Bagneux, France; 5 Bristol-Myers Squibb, Princeton, NJ, USA; 6 Rush Presbyterian/St. Luke's Medical Center, Chicago, IL, USA; 7 Centre Hospitalier Universitaire de Grenoble, Grenoble, France OBJECTIVES: The Irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated a 20% and 23% reduction compared to no treatment or amlodipine respectively in the combined endpoint of doubling of serum creatinine (DSC), end-stage renal disease (ESRD) or death in patients with hypertension (treated with all antihypertensive drugs except ACE-inhibitors and Ca-antagonists), type 2 diabetes and overt nephropathy (H-T2DM-N). A simulation model was developed to project the long-term cost-consequences of the IDNT in Belgium and France.
METHODS:
A Markov model simulated progression from nephropathy to DSC, ESRD, death, and cardiovascular events in H-T2DM-N treated with irbesartan, amlodipine, or placebo. Treatment-specific probabilities were derived from IDNT. Country-specific ESRD-related transition probabilities were retrieved to reflect local management practices and ESRD outcomes. Countryspecific costs were derived from published sources. A 25year time horizon was used. Mean total lifetime costs (TC) and life expectancy (LE) were calculated for patients with baseline age 59 years (mean age of the IDNT population). Future costs and benefits were discounted at 3% p.a. Sensitivity analysis was performed to identify parameters with an important impact, and to assess the effect of varying key assumptions on the robustness of the model. RESULTS: In Belgium, irbesartan lead to improved LE of 0.62 years and 0.42 years, and projected 25 year TC savings of €11,776 and €20,132/patient versus no treatment or amlodipine respectively. In France, improvements in LE were similar, but cost savings were greater (TC savings of €14,382 and €23,249 versus placebo or amlodipine respectively). The results were robust under a wide range of plausible assumptions. CONCLUSIONS: Treating hypertensive type 2 diabetes patients with nephropathy using irbesartan was both cost-and life-saving compared to amlodipine or antihypertensive therapy alone.
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PDB5
LONG-TERM CONSEQUENCES FOR THE TREATMENT OF HYPERTENSIVE DIABETES TYPE 2 PATIENTS WITH A FIXED COMBINATION OF AN ACE-INHIBITOR AND NON-DIHYDROPYRIDINE-CALCIUM-CHANNEL-BLOCKER IN COMPARISON TO OTHER COMBINATION THERAPIES
Maxion-Bergemann S 1 , Wittenberg W 2 , Bergemann R 1 1 Institute for Medical Outcome Research, Lörrach, Germany; 2 Abbott GmbH & Co. KG, Ludwigshafen, Germany OBJECTIVE: Comparing a fixed combination of an ACE-inhibitor and a Non-Dihydropyridine-Calcium-Channel-Blocker (trandolapril/verapamil) with other medications in the treatment of hypertensive type-2 diabetics to determine medical consequences of a beneficial metabolic effect as judged by HbA1c value. METHODS: A computer model was developed in order to assess longterm effects of various levels of HbA1c on diabetesrelated complications for hypertensive patients with diabetes type-2, who were treated with fixed antihypertensive combinations. Data from 2 clinical studies were extrapolated to 10 years. The expected event rate was calculated per treatment group, based on UKPDS data. Complications included in the model: renal failure, photocoagulation, vitreous hemorrhage, blindness, cataract extraction, amputation, myocardial infarction, angina, heart failure, and non-fatal stroke. RESULTS: The ACE/CCB-combination showed a beneficial effect on HbA1c values, and the resulting event rate in this group is lower than for patients treated with fixed combinations like atenolol/chlorthalidone or enalapril/hydrochlorothiazide. Extrapolating data from one study, the relative risk was lowered by 20% for most diabetes-related events in comparison to atenolol/chlorthalidone. "Cataract extraction" and "renal failure" were reduced by 19%, "blindness" by 30%. The risk reduction for CVD amounted 13% for non-fatal myocardial infarction, 12% for non-fatal stroke. In the second study, the relative risk for "Cataract extraction" is reduced by 16% in the ACE/CCB-group after 10 years, compared to the patient group treated with a combination enalapril/ hydrochlorothiazide. The risk reduction for CVD amounted 17% for non-fatal myocardial infarction and 16% for non-fatal stroke. CONCLUSION: The use of this computerized model allows gaining insight into the long-term medical outcomes of the treatment with ACE/ CCB-combination in hypertensive type-2 diabetics. The model shows a beneficial effect for the combination trandolapril/verapamil in diabetic patients because of the additional HbA1c decreasing effect beside the hypertension management.
PDB6
RETROSPECTIVE STUDY EVALUATING CLINICAL AND ECONOMIC OUTCOMES OF MONOTHERAPY VERSUS DUAL THERAPY IN DIABETIC PATIENTS IN A COUNTY HEALTH CARE SYSTEM
Lal LS 1 , Ogbonnaya K 2 , Mbah T 3 1 Texas Southern University, Houston, TX, USA; 2 Baylor College of Medicine, Houston, TX, USA; 3 Harris County Hospital District, Houston, TX, USA OBJECTIVE: The primary objective is to evaluate the clinical and economic outcomes of monotherapy with a sulfonylurea versus dual therapy with metformin and a sulfonylurea in a county health care system. METHODS: This is a retrospective, chart-review, study in which the patients will serve as their own controls, prior to starting dual therapy. All patients are evaluated two years prior to and post the addition of the second agent, metformin. Data collected will include the following: HbA1C, fasting blood glucose, lipid profile, and liver and renal function tests, adverse drug reactions, number of hospital and emergency room admissions, number and type of clinic visits, and number of operations/procedures/and diagnostic tests. The t-test for paired data is utilized to analyze the continuous variables. RESULTS: A total of 124 patients enrolled in this study, with a mean duration of diabetes of 6.68 years (SD 4.62). The average HbA1c on monotherapy is 10.5% versus 10.2% on dual therapy (NS). The average fasting blood glucose is 229 mg/dL on monotherapy versus 192 mg/dL on dual therapy (p < 0.05). For the economic outcomes on monotherapy there is an average of 1.31 visits per patient versus 1.43 visits on dual therapy to the emergency room, hospital, and to ambulatory care clinics. On monotherapy, 31% of the patients had procedures and 37% had diagnostic tests, compared to 38% and 51% respectively, on dual therapy. CONCLUSIONS: This study does point to better clinical outcomes with dual therapy; however, there is a concurrent rise in the resource utilization. This increase could be due to more education on the physician side for preventive practices and to an increase in the patient access within the system. More research, especially prospectively designed studies, need to be conducted to determine the exact clinical and economic impact of dual oral therapy for diabetes.
